Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $5240.0.

  • China SXT Pharmaceuticals' Current Deferred Revenue rose 29581.46% to $5240.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5240.0, marking a year-over-year increase of 29581.46%. This contributed to the annual value of $58627.0 for FY2025, which is 6875.98% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $5240.0 for Q3 2025, which was up 29581.46% from $58627.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Current Deferred Revenue high stood at $257449.0 for Q1 2021, and its period low was -$42994.0 during Q3 2021.
  • Its 5-year average for Current Deferred Revenue is $80649.7, with a median of $61864.0 in 2022.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Current Deferred Revenue plummeted by 11977.54% in 2021, and later skyrocketed by 29581.46% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Deferred Revenue (Quarter) stood at -$42994.0 in 2021, then skyrocketed by 251.42% to $65101.0 in 2022, then tumbled by 45.95% to $35185.0 in 2023, then plummeted by 107.61% to -$2676.0 in 2024, then skyrocketed by 295.81% to $5240.0 in 2025.
  • Its Current Deferred Revenue stands at $5240.0 for Q3 2025, versus $58627.0 for Q1 2025 and -$2676.0 for Q3 2024.